Novartis to Offer Cosentyx to Cash Paying Patients at a 55% Discount

Beginning Nov. 1, 2025, Novartis will launch a direct-to-patient (DTP) platform in the United States that offers cash-paying patients prescribed Cosentyx (secukinumab) the option to purchase it at a 55% discount off the list price.

Cosentyx is a biologic that is FDA-approved to treat multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa, and psoriatic arthritis.Its list price as of July 2025 is $7,936.48 a month for either a 150-mg or a 300-mg dose strength self-injection package and $4,401.32 per intravenous infusion.

The price offered to cash-paying patients represents average savings that insurers and pharmacy benefit managers receive. The Cosentyx DTP platform serves as proof-of-concept for a direct-selling model for specialty medicines and ideally would work alongside insurance to help improve patient affordability, according to a news release.

“The launch of this new platform is a first step as we continue to work toward solutions to provide our net prices more directly to patients and make the healthcare system work better for Americans,” Victor Bultó, president, US for Novartis, said in a news release.

This move follows a trend among other pharmaceutical companies to offer direct-to-consumer platforms with cash pay programs. Last week, both AstraZeneca and Bristol Myers Squibb announced additional programs for cash-paying customers.

Beginning Oct. 1, AstraZeneca will make available a platform for patients to directly access Airsupra (albuterol/budesonide) or Farxiga (dapaglifozin) for a cash price that is up to 70% off list price. Additionally, patients will also be able to order Flumist (Influenza Vaccine Live, Intranasal) for home delivery through an online platform, AstraZenecaDirect.com.

Airsupra (albuterol/budesonide) has a list price of $489.25 for one inhaler and is an asthma rescue inhaler. It is indicated for adults 18 years of age and older to treat or prevent symptoms of asthma and to help prevent sudden severe breathing problems.

Farxiga (dapaglifozin) has a list price of $599.72 for a 30-day supply. It used to lower blood sugar in people 10 years of age and older with type 2 diabetes, as well as reduce the risk of hospitalization for heart failure, reduce the risk of cardiovascular death, and reduce the risk of kidney damage.

Bristol Myers Squibb announced that beginning in January 2026, it will offer Sotyktu (deucravacitinib) at more than 80% off the current list price to eligible, cash-paying U.S. patients, according to a news release published today. The current list price of Sotyktu is $6,828 for a 30-day supply. Sotyktu is an oral medication used to treat moderate-to-severe plaque psoriasis.

This offer builds upon Bristol Myers Squibb’s existing offer of more than 40% off the Eliquis (apixaban) list price. The current list price is $606 for a 30-day supply. Eliquis is already available through the Bristol Myers Squibb-Pfizer Alliance program, which launched this month. The medication is available for purchase through the Eliquis 360 Support website. Eliquis is an oral anticoagulant medication used in children and adults to treat blood clots in the veins of the legs and lungs, also called venous thromboembolism.

Other companies, such as Eli Lilly, Pfizer, and Novo Nordisk, also offer some of their drugs at a direct-to-consumer discount.